Active substance
Citalopram
- SFDA 15
- US FDA 39
- Health Canada 55
- US price lines 7
- NHS prices 5
- WHO EML 1
- Safety 6
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| CIPRAM 20MG TAB | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 111.30 | NCE · Prescription | H. LUNDBECK | Valid |
| CITALOGEN 10 mg film-coated tablet | 10 mg | Film-coated tablet · Oral use | 30 Blister | SAR 54.10 | Generic · Prescription | RIYADH PHARMA | Valid |
| CITALOGEN 20 mg film-coated tablet | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 85.80 | Generic · Prescription | RIYADH PHARMA | Valid |
| CITALOPRAM HEXAL 20MG F.C. TABLETS | 20 mg | Film-coated tablet · Oral use | 20 Blister | SAR 32.00 | Generic · Prescription | HEXAL | Valid |
| CITALOPRAM HEXAL 40MG F.C. TABLETS | 40 mg | Film-coated tablet · Oral use | 20 Blister | SAR 54.25 | Generic · Prescription | HEXAL | Valid |
| DEPRAN 20 mg film-coated tablet | 20 mg | Tablet · Oral use | 28 Blister | SAR 56.30 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| DEPRAN 40 mg film-coated tablet | 40 mg | Tablet · Oral use | 28 Blister | SAR 87.50 | Generic · Prescription | Middle East Pharmaceutical and Chemical Industries and Medical Appliances Co. | Valid |
| LECITAL 20MG F.C. CAPLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 34.45 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Valid |
| LOPRAM 20MG F.C. TABLETS | 20 mg | Film-coated tablet · Oral use | 28 Blister | SAR 72.05 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CITALOGEN 40 mg film-coated tablet | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 137.90 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| CITAPRAM 20MG F.C. TABLETS | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 59.25 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
| CITAPRAM 40MG F.C. TABLETS | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 100.50 | Generic · Prescription | Pharma International Co. | Withdrawn by MAH · Not Marketed |
| LECITAL 40MG F.C. CAPLETS | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 68.90 | Generic · Prescription | Jordan Sweden Medical and Sterilization Co. | Withdrawn by MAH · Not Marketed |
| LOPRA 20MG TABLET | 20 mg | Film-coated tablet · Oral use | 30 Blister | SAR 95.35 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
| LOPRA 40MG TABLET | 40 mg | Film-coated tablet · Oral use | 30 Blister | SAR 153.20 | Generic · Prescription | Tabuk Pharmaceutical Manufacturing Company | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ABDOMINAL SPASM; ALZHEIMER / DEMENTIA; ANXIETY DISORDERS; ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD); AUTISM SPECTRUM DISORDER; DEPRESSION; FIBROMYALGIA; HUNTINGTON'S DISEASE-TICS; IRRITABLE BOWEL SYNDROME; MENOPAUSE; NEUROPATHIC PAIN; PAIN MANAGEMENT IN CANCER PATIENTS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| CELEXA | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ABBVIE | Prescription | 17 Jul 1998 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | AUROBINDO | Prescription | 28 Oct 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | DR REDDYS LABS LTD | Prescription | 28 Oct 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | MYLAN | Prescription | 5 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | CHARTWELL MOLECULAR | Prescription | 5 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE/5ML | solution · oral | HIKMA PHARMS | Prescription | 13 Dec 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 40MG BASE; EQ 20MG BASE; EQ 10MG BASE | tablet · oral | EPIC PHARMA | Prescription | 29 Apr 2005 |
| CITALOPRAM HYDROBROMIDE | 40MG | tablet · orally disintegrating | BIOVAIL LABS INTL | Prescription | 20 Dec 2005 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE/5ML | solution · oral | CHARTWELL MOLECULAR | Prescription | 14 Jun 2006 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE/5ML | solution · oral | AUROBINDO PHARMA | Prescription | 28 Aug 2006 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | INVAGEN PHARMS | Prescription | 3 Oct 2006 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | TORRENT PHARMS | Prescription | 27 Mar 2007 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE/5ML | solution · oral | HETERO LABS LTD III | Prescription | 15 Dec 2015 |
| CITALOPRAM HYDROBROMIDE | EQ 30MG BASE | capsule · oral | ALMATICA | Prescription | 31 Jan 2022 |
| CITALOPRAM HYDROBROMIDE | EQ 30MG BASE | capsule · oral | AUROBINDO PHARMA LTD | Prescription | 13 Mar 2026 |
| CELEXA | EQ 60MG BASE | tablet · oral | ABBVIE | Discontinued | 17 Jul 1998 |
| CELEXA | EQ 10MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · oral | FOREST LABS | Discontinued | 22 Dec 1999 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | HERITAGE PHARMA | Discontinued | 28 Oct 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | FOSUN PHARMA | Discontinued | 28 Oct 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | EPIC PHARMA LLC | Discontinued | 28 Oct 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 5 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | SUN PHARM INDS INC | Discontinued | 12 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | COSETTE PHARMS NC | Discontinued | 16 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | ROXANE | Discontinued | 23 Nov 2004 |
| CITALOPRAM HYDROBROMIDE | EQ 10MG BASE; EQ 20MG BASE; EQ 40MG BASE | tablet · oral | APOTEX | Discontinued | 24 Nov 2004 |
14 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-CITALOPRAM | 02339390 | 20 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM | 02339404 | 40 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM | 02374617 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM TABLETS | 02513676 | 10 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM TABLETS | 02513684 | 20 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM TABLETS | 02513692 | 40 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| AG-CITALOPRAM TABLETS | 02543060 | 30 MG | TABLET · ORAL | ANGITA PHARMA INC. |
| APO-CITALOPRAM | 02246056 | 20 MG | TABLET · ORAL | APOTEX INC |
| APO-CITALOPRAM | 02246057 | 40 MG | TABLET · ORAL | APOTEX INC |
| AURO-CITALOPRAM | 02275562 | 20 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-CITALOPRAM | 02275570 | 40 MG | TABLET · ORAL | AURO PHARMA INC |
| CELEXA 20 MG | 02239607 | 20 MG | TABLET · ORAL | LUNDBECK CANADA INC |
| CELEXA 40 MG | 02239608 | 40 MG | TABLET · ORAL | LUNDBECK CANADA INC |
| CITALOPRAM | 02353660 | 20 MG | TABLET · ORAL | SANIS HEALTH INC |
| CITALOPRAM | 02353679 | 40 MG | TABLET · ORAL | SANIS HEALTH INC |
| CITALOPRAM | 02387948 | 10 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CITALOPRAM | 02387956 | 20 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CITALOPRAM | 02387964 | 40 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| CITALOPRAM | 02430517 | 10 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| CITALOPRAM | 02430541 | 20 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| CITALOPRAM | 02430568 | 40 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| CITALOPRAM | 02445719 | 10 MG | TABLET · ORAL | SANIS HEALTH INC |
| CTP 30 | 02296152 | 30 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| JAMP-CITALOPRAM | 02313405 | 20 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-CITALOPRAM | 02313413 | 40 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
30 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | CELEXA 20 MG TABLET | $9.00923 | per EA | 23 Sep 2026 |
| US NADAC | CELEXA 40 MG TABLET | $9.469 | per EA | 23 Sep 2026 |
| US NADAC | CITALOPRAM HBR 10 MG TABLET | $0.02604 | per EA | 23 Sep 2026 |
| US NADAC | CITALOPRAM HBR 10 MG/5 ML SOLN | $0.17955 | per ML | 23 Sep 2026 |
| US NADAC | CITALOPRAM HBR 20 MG TABLET | $0.0296 | per EA | 23 Sep 2026 |
| US NADAC | CITALOPRAM HBR 30 MG CAPSULE | $4.76996 | per EA | 23 Sep 2026 |
| US NADAC | CITALOPRAM HBR 40 MG TABLET | $0.04136 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Citalopram 10mg tablets | £0.75 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Citalopram 20mg tablets | £0.84 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Citalopram 30mg tablets | £14.40 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Citalopram 40mg tablets | £0.85 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Citalopram 40mg/ml oral drops sugar free | £7.15 | 15 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 24.3. Medicines for anxiety disorders · core (EML); complementary (EMLc)
Therapeutic equivalent to fluoxetine for Generalised anxiety disorder
Safety signals and safety-related labeling changes
- US FDA 19 Apr 2024 CELEXA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 18 Aug 2023 CITALOPRAM HYDROBROMIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 1 Oct 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: Yes - EMA PRAC 11 Jun 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - EMA PRAC 12 Mar 2020 PRAC signal: Postpartum haemorrhage
Action for MAH: update of the product information: No - MHRA 18 Jul 2016 Citalopram: suspected drug interaction with cocaine; prescribers should consider enquiring about illicit drug use
Possible illicit drug use should be considered when prescribing medicines that have the potential to interact adversely.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.